Robert Redfield says he's "proud" of work on President Trump's initiative but believes COVID vaccines should be "critically ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

The shift to a clear recommendation for vaccination goes beyond the prior guidance "just to encourage adults to talk to their ...

Earlier in October, Pfizer Inc (NYSE: PFE ... budget by $1.1 billion over the next three years while it aims to get FDA ...

It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...

The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Moderna has secured FDA approval for its respiratory ... effect seen with both GSK and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...